ICP-490

DRUG2 trials

Sponsors

Beijing InnoCare Pharma Tech Co., Ltd.

Conditions

Relapsed and/or Refractory Multiple MyelomaRelapsed or Refractory Non-Hodgkin Lymphoma

Phase 1

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

RecruitingNCT05719701

Beijing InnoCare Pharma Tech Co., Ltd.Relapsed and/or Refractory Multiple Myeloma

Start: 2023-03-29End: 2025-12-30Target: 80Updated: 2024-04-09

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Not yet recruitingNCT06845241

Beijing InnoCare Pharma Tech Co., Ltd.Relapsed or Refractory Non-Hodgkin Lymphoma

Start: 2025-02-28End: 2028-12-31Target: 68Updated: 2025-02-25